Regd. Office: 301, E - Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, INDIA. Tel.: 022-40842222, 26108030, Email: info@nglfinechem.com, CIN: L24110MH1981PLC025884, Website: www.nglfinechem.com

August 10, 2022

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai — 400 001.

To, Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No.C/1, G Block, Bandra Kurla Complex, Bandra East, Mumbai 400050.

Sub: Resubmission of Unaudited Financial Results for the quarter ended June 30, 2022.

Scrip Code: 524774 Symbol: NGLFINE

Dear Sir/Madam,

With reference to the submission of the Unaudited Financial Results of the Company for the quarter ended June 30, 2022, we would like to inform you that due to inadvertent typographical error in the Gain/(Loss) on actuarial valuation of post-employment benefits under Other Comprehensive Income column, the figure mentioned is (9.47) instead of (9.65).

We hereby resubmit the Unaudited Financial Results for the quarter ended on June 30, 2022.

We apologies for the inconvenience caused to you and request you to update the same in your records,

CHE

Thanking you,

Yours faithfully,

For NGL Fine-Chem Limited

Pallavi Pednekar

Company Secretary & Compliance Officer

Membership No: A33498

Encl: As Above.

## **NGL FINE-CHEM LIMITED**

Regd Office: 301 E Square, Subhash Road, Vile Parle East), Mumbai 400 057, Maharashtra, India.

CIN: L24110MH1981F\_C#25884

dia

## UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2022 UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2022

					Rupees in lakhs						Rupaes in Jakhs
	Particulars		Quarter ended	g	Year ended		Particulars		Quarter ended		Year ended
		30.06.2022	31.03.2022	30.06.2021	31.03.2022			30.06.2022	2 31.03.2022	30.06.2021	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)			(Unaudited)	1) (Audited)	(Unaudited)	(Audited)
_	Revenue from Operations	6,460.96	96 8,406.38	3 7,586.28	31,750.30	-	F-venue from Operations	6,293.71	7,821.33	3 7,590.88	31,866.74
=	Other Income	314.13	13 297.64	455.05	1,068.25	=	Cher Income	364.74	74 227.85		1,263.99
≡	Total Revenue (I+II)	6,775.09	9 8,704.02	8,041.33	32,818.55	≡	T⊐al Revenue (I+II)	6,658.45	15 8,049.18	89	33,130.73
≥	Expenses:					≥	Expenses :			L	
	a) Cost of Material Consumed	3,098.29	4,898.57	3,433.30	16,967.13		■ O⊪st of Material Consumed	3,124.25	4,701.12	3,411.25	17,034.64
	b) (Increase)/Decrease in stock in trade and work in progress	426.15	(905.47)	(207.68)	(2,268.02)		<ul> <li>(Ir crease)/Decrease in stock in trade and work in progress</li> </ul>	368.04			(2,203,14)
	c) Employee benefits expenses	86.688	927.06	746.10	3,485.27		c_ Employee benefits expenses	826.68	867.11		3,305.04
	d) Finance Costs	49.80	153.51	1 37.01	156.16		c_Fi⊪ance Costs	49.80	37.35		156.16
	e) Depreciation and amortisation expenses	360.49	347.68	3 217.81	1,036.90		E_ Depreciation and amortisation expenses	195.78		193.34	767.31
	f) Other expenses	1,896.29	2,429.86	3 1,257.89	6,781.47		f Other expenses	2,027.26	2,089.05	1,355.71	7,173.32
	Total Expenses (IV)	6,721.00	7,851.21	5,484.43	26,158.91		T⊐al ≅xpenses (IV)	6,591.81	1,047.39	5,508.55	26,233.33
>	Profit/(loss) before exceptional items and tax (III-IV)	54.09	952.81	2,556.90	6,659.63	>	P⊃ftt(loss) before exceptional items and tax (III-IV)	66.64	1,001.79	2,574.56	6,897.40
>	Exceptional Items			•	,	5	E-ceptional Items	•		,	
₹	Profit/(loss) Before Tax (V-VI)	54.09	19 852.81	2,556.90	6,659.63	₹	P-rit (loss) Before Tax (V-VI)	66.64	1,001.79	2,574.56	6,897.40
₹	Tax Expense					₹	T¥ Expense				
	a) Current Tax	(87.50)	(295.50)	(605.50)	(1,715.00)		a Current Tax	(87.50)	(305.00)	(000:00)	(1,715.00)
	b) MATTax	•		•			b M⊾TTax		_	'	,
	c) Prior Years			•			b Pror Years		•	ī	
	d) Deffered Tax	85.18	8 129.41	(38.82)	45.09		c. Deffered Tax	72.05	98.88	(39.69)	42.25
×	Profit/ (Loss) for the period from continuing operations (VII-VIII)	51.77	7 686.72	1,912.58	4,989.71	×	P->fit (Loss) for the period from continuing operations (VII-VIII)	51.19	9 785.75	1,934.87	5,224.65
×	Other Comprehensive Income					×	C_ner Comprehensive Income				
	a. Gain/(Loss) on actuarial valuation of post employment benefits	(9.65)	(5) 8.54	2.10	(7.49)		உ செ்n/(Loss) on actuarial valuation of post employment benefits	(9.45)	15) 8.67	2.12	(7.13)
	b. Deferred tax on above	2.39	(2.15)	(0.53)	1.89		L. Deferred tax on above	2.38	(2.18)	(0.54)	1.79
	c. Other Comprehensive Income (Net of Tax)	(7.26)	(9)	1.57	(5.60)		C. Other Comprehensive Income (Net of Tax)	(7.07)	07) 6.49	1.58	(5.33)
≂	Total Comprehensive Income	44.51	1 693.11	1,914.15	4,984.11	×	T=al Somprehensive Income	44.12	792.24	1,936.45	5,219.32
₹	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	₹	P≡d-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90
X	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	A. X.	A.N.	Z.A.	20,012.89	\ X	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	A.N.A	N.A	20,347.57
≥×	Earnings Per Share (EPS)					λIX	E≡nings Per Share (EPS)				
	a) Basic	₹ 0.84	4 ₹ 11.12	€ 30.96	₹ 80.77		a, Basic	₹ 0.83	33 ₹ 12.72	₹ 31.32	₹ 84.57
	b) Diluted	₹ 0.84	4 ₹ 11.12	₹ 30.96	₹ 80.77		b_Diluted	₹ 0.83	33 ₹ 12.72	₹ 31.32	₹ 84.57

## Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 10th Aug, 2022. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- 2 The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- 3 The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrotech Polychem Private Limited.
- 4 Previous period figures have been regrouped/rearranged wherever necessary.

## Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 10th A \_guet, 2022. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- 2 The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Cnoerating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- 3 Pavicus period figures have been regrouped/rearranged wherever necessary.

For and On behalf of Board of Directors

RAHUL JAYANT NACHANE

Digitaly signed by RAHUL ANYANT MCHAME Disc. 2022.0811 14.0215.405307 Rahull Nachane Managing Director DIN 00223346

Place: Mumbai Date: 10-Aug-22